Ömer Faruk Turan

Ömer Faruk Turan

Auto-generated profile, based on publicly available information

Ömer Faruk Turan

Department of Neurology, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2024 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
EKEmine Rabia Koç
Emine Rabia Koç
GGGüllü Gizem
Güllü Gizem
FSFurkan Sarıdaş
Furkan Sarıdaş
SGSanja Gluscevic
Sanja Gluscevic
BCBelkis Nihan Coşkun
Belkis Nihan Coşkun
TFTuran Omer Faruk
Turan Omer Faruk

10 September 2021 in Neurological Research
Verified
Journal Article
Closed access
FSFurkan Sarıdaş
Furkan Sarıdaş
HUHavva Tezcan Unlu
Havva Tezcan Unlu
GCGulsah Cecener
Gulsah Cecener
UEUnal Egeli
Unal Egeli
MTMaryam Sabour Takanlou
Maryam Sabour Takanlou
OTOzlem Taskapilioglu
Ozlem Taskapilioglu
Multiple sclerosis (MS) is an inflammatory, autoimmune demyelinating, and neurodegenerative disorder of the central nervous system. Interactions between environmental factors, predisposition genes, and determining genes appear to be involved in its etiology. Epigenetic mechanisms such as microRNA-mediated gene regulation can determine the susceptibility and severity of autoimmune diseases. Therefore, to determine the role of miR-146a and miR-155 in MS and its developmental stages, the expression levels in the serum of MS and clinically isolated syndrome (CIS) patients were compared with those of healthy controls. In the present study, the expression levels of miR-146a and miR-155 were assessed using quantitative Real-Time PCR in blood samples of 15 CIS patients and 61 relapsing-remitting multiple sclerosis (RRMS) patients alongside 32 healthy patients as controls. Furthermore, any associations with the clinicopathologic variables of the patients were also evaluated. Dysregulations were found only in the miR-146a and miR-155 expressions in the RRMS-Control group. When the RRMS patients were evaluated in terms of the characteristics of sex, annual attack rate, age of diagnosis, duration of follow-up, and immunomodulatory treatments used, no significant differences were observed. However, significant dysregulations were identified in miRNA expression in the vitamin D level, EDSS values, and the number of attacks. ROC curve analysis showed that miR-146a and miR-155 were significant in the RRMS-Control group for the area under the curve (AUC). It is possible that miR-146a may be associated with vitamin D deficiency and disease disability, while miR-155 may be associated with the number of attacks.

1 March 2011 in Clinical Neuroradiology
Verified
Journal Article
Closed access
PDF file
OTO. Taskapilioglu
O. Taskapilioglu
SYS. Yurtogullari
S. Yurtogullari
EYEmel Yilmaz
Emel Yilmaz
BHB. Hakyemez
B. Hakyemez
SYS. Yilmazlar
S. Yilmazlar
IBI. Bora
I. Bora

30 August 2024 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
FSFurkan Sarıdaş
Furkan Sarıdaş
FHFarid Hojjati
Farid Hojjati
SAShanay Alizada
Shanay Alizada
SLSarra Lazrak
Sarra Lazrak
EKEmine Rabia Koç
Emine Rabia Koç
OTOmer Faruk Turan
Omer Faruk Turan

3 January 2019 in The European Research Journal
Verified
Journal Article
Open access
PDF file
VKVahap Ozan Kotan
Vahap Ozan Kotan
ZKZeynep Kotan
Zeynep Kotan
BABirgül Aydın
Birgül Aydın
OTOzlem Taskapilioglu
Ozlem Taskapilioglu
BABerna Alkan
Berna Alkan
SKSelçuk Kırlı
Selçuk Kırlı
Objectives: Multiple Sclerosis (MS) is a chronic disease which affects physical,psychological and social functioning of patients. In this study we aim to indicate psychiatric comorbidity, some psychosocial factors and their associations with quality of life in patients with MS. Methods: A total of 227 patients underwent psychiatric examination and the following scales were applied: Socio-demographic data form, Hospital Anxiety and Depression Scale (HADS), Multiple Sclerosis Quality of Life-54 (MSQOL-54), Psychosocial Adjustment to Illness Scale-Self report (PAIS-SR) and Multidimensional Scale of Perceived Social Support (MSPSS). Results: Among 227 patients with MS, 67.8% (n = 154) had psychiatric diagnosis; 24.2% (n = 55) had depression,19.8% (n = 45) had adjustment disorder, 14.9% (n = 34) had anxiety disorder, 7.1% (n=16) had dysthymic disorder and 1.8% (n = 4) had bipolar disorder. Patients with a psychiatric diagnosis had lower scores in role limitations due to emotional problems, emotional well-being, health perceptions, social function, cognitive function, health distress and mental health composite of MSQOL-54. PAIS-SR and MSPSS scores were significantly lower in MS patients with a psychiatric diagnosis. PAIS-SR scores were negatively correlated with role limitations-emotional, emotional well-being, social function, sexual function, satisfaction with sexual function, physical health composite and mental health composite scores of MSQOL-54. MSPSS total score was positively correlated with emotional well-being score of MSQOL-54. Conclusions: In MS patients, there is a high prevalence of psychopathology and it is associated with quality of life, perceived social support and psychosocial adjustment of the patients. Quality of life is reduced especially in emotional and mental aspects in patients with a psychiatric diagnosis. Diagnosis and treatment of psychopathology in MS patients seems crucial to decrease disease burden.

31 August 2023 in International Journal of Neuroscience
Verified
Journal Article
Closed access
EKEmine Rabia Koç
Emine Rabia Koç
TFTuran Ömer Faruk
Turan Ömer Faruk
SFSaridas Furkan
Saridas Furkan
ELElhamida Sarra Lazrak
Elhamida Sarra Lazrak
POPinar Acar Ozen
Pinar Acar Ozen
ATAslı Tuncer
Aslı Tuncer
Neuromyelitis optica (NMO) is an inflammatory, autoimmune and demyelinating disease of the central nervous system and is often characterized by attacks of severe optic neuritis and long segment myelitis. Identifying the disease-specific pathogenic anti-AQP4 autoantibody in NMOSD has allowed the development of highly effective disease-modifying drugs in the treatment phase. Eculizumab is a humanized antibody that binds to complement C5 and inhibits the formation of the C5b-induced membrane attack complex. It is approved for treating many diseases in which tissue damage is accompanied by complement (such as neuromyelitis optica, myasthenia gravis, autoimmune hemolytic anemia, and paroxysmal hemoglobinuria). We present a patient diagnosed with NMO who developed possible drug-induced liver injury three months after the start of eculizumab treatment. After discontinuing eculizumab treatment, liver function tests gradually regressed in a month. Eculizumab-associated hepatotoxicity is a previously unreported adverse event in NMOSD patients. Therefore, patients should be monitored for liver function tests during eculizumab treatment, and care should be taken for hepatotoxicity. If hepatotoxicity is detected while under eculizumab treatment, patients should be investigated for other drug use, complementary food supplementation, or possible autoimmune hepatitis, and other potential causes should be excluded.